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Abstract
Background An increasing number of studies indicate that exercise plays an important role in the overall care of prostate
cancer (PCa) patients before, during and after treatment. Historically, research has focused on exercise as a modulator of
physical function, psychosocial well-being as well as a countermeasure to cancer- and treatment-related adverse effects.
However, recent studies reveal that exercise may also directly influence tumour physiology that could beneficially affect the
response to radiotherapy.
Methods In this narrative review, we provide an overview of tumour vascular characteristics that limit the effect of radiation
and establish a rationale for exercise as adjunct therapy during PCa radiotherapy. Further, we summarise the existing
literature on exercise as a modulator of tumour perfusion and hypoxia and outline potential future research directions.
Results Preclinical research has shown that exercise can reduce intratumoral hypoxia—a major limiting factor in radio-
therapy—by improving tumour perfusion and vascularisation. In addition, preliminary evidence suggests that exercise
training can improve radiotherapy treatment outcomes by increasing natural killer cell infiltration in a murine PCa model.
Conclusions Exercise is a potentially promising adjunct therapy for men with PCa undergoing radiotherapy that may
increase its effectiveness. However, exercise-induced tumour radiosensitisation remains to be confirmed in preclinical and
clinical trials, as does the optimal exercise prescription to elicit such effects.
Introduction
Radiotherapy is a cornerstone in the management of cancer
and used to treat a myriad of malignancies, including
prostate. Approximately 50% of all cancer patients receive
radiotherapy during the course of their treatment for either
curative or palliative purposes [1]. Moreover, ~40% of
prostate cancer (PCa) patients aged 65 and above receive
radiotherapy as their primary treatment [2]. Despite ever
evolving technological advances that allow for more precise
targeting of tumours, treatment resistance and subsequent
disease recurrence pose a significant challenge in the field of
radiation oncology [3–5].
Approximately 20–39% of patients with localised PCa
treated with external beam radiotherapy experience local
disease persistence and subsequent recurrence with an
increased risk of developing distant metastases [6–8]. The
hypoxic tumour microenvironment (TME) is recognised as
a major limiting factor in the treatment of cancer and is an
established prognostic marker that has been associated with
treatment resistance as well as local disease persistence and
recurrence [9, 10]. Moreover, hypoxia is a common feature
of many solid tumours, including PCa [11].
While exercise has been associated with a reduced risk of
PCa progression and mortality [12], little is known about
the underlying biological mechanisms contributing to these
benefits. It has been postulated that exercise may acutely
reduce tumour hypoxia through increased perfusion of
tumour tissue and that structural adaptations of the tumour
vasculature in response to exercise training may potentially
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result in a less aggressive tumour and further enhance
treatment response [13].
Given the significance of hypoxia in compromising
cancer treatment, the purpose of this narrative review is to:
(1) provide an overview of the characteristics of tumour
vasculature and how they affect tumour hypoxia; (2)
establish a rationale for exercise as adjunct therapy during
cancer treatment; (3) summarise the existing literature on
exercise as a modulator of tumour perfusion and hypoxia;
and (4) outline potential future research directions.
Tumour vasculature and hypoxia
Angiogenesis is a normal physiological process that occurs
in situations like wound healing or in response to exercise
training [14, 15]. In tumours, however, rapid proliferation of
cells results in the formation of hypoxic areas and sub-
sequent persistent local and unbalanced expression of pro-
and anti-angiogenic factors leads to the formation of dys-
functional and structurally abnormal vascular networks,
which are a characteristic feature of the TME [16]. These
vascular networks are often very disorganised, tortuous and
immature, which results in heterogeneous and variable
tumour blood flow, further aggravating rather than alle-
viating hypoxia [17, 18]. Consequently, hypoxic and thus
angiogenic signalling are sustained, further driving abnor-
mal tumour vascularisation. In addition, tumour blood
vessels are leakier than normal blood vessels, resulting in
increased interstitial fluid pressure (IFP) [19]. Increased IFP
can lead to sudden, intermittent perfusion changes as a
result of collapsing blood vessels, which, in turn, limits
oxygen delivery to the tumour, further worsening tumour
hypoxia and decreasing treatment efficacy [20]. Moreover,
increased vascular permeability plays a key role in metas-
tasis by facilitating intravasation of cancer cells [21].
Hypoxia arising from vascular abnormalities can be
differentiated into two forms—chronic and acute [22, 23].
Chronic hypoxia arises when the distance between blood
vessels and tumour cells surpass the diffusion distance of
oxygen. Chronic hypoxia is therefore also known as
diffusion-limited hypoxia. When oxygen diffuses from
blood vessels into the adjacent tissue it is consumed by the
tumour cells closest to the perfused vessel, creating a gra-
dient in the partial pressure of oxygen (PO2). The decrease
in PO2 with increasing distance from the perfused vessel
renders tumour cells further away from this vessel more
hypoxic. Acute hypoxia, on the other hand, is caused by
limited and varying perfusion of blood vessels supplying
tumour cells (i.e. perfusion-limited hypoxia). As a result, all
cells that are normally supplied by a now transiently com-
promised blood vessel are temporarily, or acutely, hypoxic.
The reasons for acutely limited perfusion are numerous and
include occlusion of vessels with blood or circulating
tumour cells, collapse of vessels due to high IFP, and
spontaneous vasoconstriction in normal tumour vessels that
then affect downstream tumour vessels [22, 23]. In addition
to poor tumour perfusion and oxygen diffusion, anaemia is
a further major cause of tumour hypoxia (i.e. anaemic
hypoxia) that results from cancer- and treatment-associated
reduced oxygen transport capacity of the blood [24, 25].
With decreasing tissue oxygen levels, tumour cells
become increasingly resistant to ionising radiation due to
reduced availability of oxygen to stabilise DNA strand
breaks caused by radiation and reactive oxygen species
[23, 26]. In PCa, hypoxia is associated with a more
aggressive tumour phenotype, increased metastasis, and
patients with more hypoxic tumours have a poorer prog-
nosis compared to patients with a less hypoxic TME [27].
Milosevic et al. [28] directly measured tumour hypoxia with
a transrectal needle-electrode technique in 247 patients with
localised PCa before radiotherapy and found that hypoxia
was associated with early biochemical failure and local
disease recurrence. Intrinsic markers of tumour hypoxia (i.e.
hypoxia-inducible factor 1-alpha) have also been investi-
gated and increased expression identified patients with
shorter time to biochemical failure independent of clinical
tumour stage, biopsy Gleason score, serum prostate-specific
antigen concentration, and radiotherapy dose [29]. Target-
ing and reversing tumour hypoxia thus has been proposed
as a potential mechanism to improve treatment response to
radiotherapy and enhance survival [27].
Pharmacological interventions aimed at inducing vas-
cular normalisation to improve treatment efficacy through
increased drug delivery and tumour oxygenation have pri-
marily focused on suppressing vascular endothelial growth
factor (VEGF) signalling given its key role in angiogenesis
[30]. Anti-angiogenic (or anti-VEGF) therapy, originally
developed to disrupt a tumour’s blood supply and deprive it
of oxygen and nutrients, has shown some promise in nor-
malising tumour vasculature when given in low doses, but
has thus far not been tested in prospective clinical trials to
permit concrete conclusions [30, 31]. Furthermore, tumour
vascular normalisation has a small therapeutic window, is
complicated by tumour heterogeneity, and associated with
significant side effects as well as malignant progression
[32–35]. Hence, the use of pharmacological angiogenesis
inhibitors has not gained wide clinical application. On the
other hand, mild hyperthermia is increasingly being
explored as a radiosensitiser for its effects on tumour vas-
culature and DNA repair mechanisms [36]. Relatively
low temperatures of 39–42 °C have been shown to increase
tumour perfusion, thus decreasing hypoxia and enhancing
tumour radiosensitivity [36]. In a recent study using an
orthotopic PCa mouse model, hyperthermia significantly
slowed tumour growth and resulted in significantly smaller
O. Schumacher et al.
normalised nadir tumour volumes compared to radiotherapy
without hyperthermia [37]. Similar to anti-VEGF therapy,
though, the timing and dosing of hyperthermia to achieve
the desired radiosensitising effect is complex and makes
clinical application challenging [36].
Exercise as adjunct therapy in cancer
treatment
In the field of exercise oncology, i.e. the application of
exercise as medicine in the oncology setting, there is con-
sistent evidence that greater levels of physical activity,
commonly defined as ‘any bodily movement produced by
skeletal muscles that results in energy expenditure’ [38], are
associated with a lower risk of developing certain types of
cancer as well as decreased all-cause and cancer-specific
mortality for patients diagnosed with breast, colorectal, or
PCa [39]. For example, Kenfield et al. [40] found that men
with PCa who did ≥3 h/week of vigorous physical activity
had a 49% lower risk of all-cause mortality and a 61%
lower risk of dying from PCa compared to men who did <1
h/week of vigorous physical activity. Furthermore, Richman
et al. [41] reported that men with localised PCa who walked
at a brisk pace for ≥3 h/week had a 57% lower risk of
disease progression compared to men who walked at an
easy pace for <3 h/week. This association between walking
pace and reduced risk of cancer progression was indepen-
dent of walking duration [41], suggesting that not only the
volume of physical activity but also the intensity of physical
activity is an important factor regarding clinical outcomes in
PCa. It is important to note, however, that these findings are
based on observational data and randomised controlled
trials are currently investigating the impact of exercise on
overall survival in patients with PCa as well as colon cancer
[42, 43].
In addition to reduced risk of disease progression and
mortality, physical activity and exercise, defined as ‘a
subset of physical activity that is planned, structured, and
repetitive and has as a final or an intermediate objective the
improvement or maintenance of physical fitness’ [38], are
increasingly being recognised as an important part of
treatment during active therapy to improve or maintain
physical function and quality of life in cancer patients [44].
Research has consistently demonstrated that exercise
improves physical and mental health in men with PCa
during and following completion of therapeutic interven-
tions and can reduce the level of fatigue experienced by
Fig. 1 Potential tumour
physiology at rest (left side)
and during exercise (right
side). a Acute exercise increases
tumour blood flow and tumour
vascular resistance is reduced.
b Augmented tumour perfusion
pressure as a result of increased
tumour blood flow may lead to
greater oxygen (O2) diffusion
distance and thus reduce
diffusion-limited hypoxic
tumour areas. c Tumour
vasculature is dysfunctional and
structurally abnormal, resulting
in heterogeneous and variable
tumour blood flow. Exercise
increases the area of tumour
perfusion and therefore reduces
perfusion-limited hypoxia.
Created with BioRender.com.
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many patients [45–48]. Some studies have also indicated
that exercise may help alleviate toxicities associated with
treatment [49, 50].
More recently, the role of exercise as an adjunct therapy
to enhance the effectiveness of conventional cancer treat-
ments such as radiotherapy is gaining a strong interest for
its effects of modulating tumour vasculature and oxygena-
tion [51, 52]. Potential tumour physiological responses to
exercise are shown in Fig. 1. However, mechanistic insight
regarding the benefits of exercise on cancer biology is
currently limited. Acute exercise bouts as well as exercise
training are characterised by distinct physiological respon-
ses and result in specific immediate and chronic adaptations.
It is well established that exercise leads to vascular adap-
tations in humans [53]. For example, exercise training
improves oxygen delivery to peripheral tissues through
Exercise
Stroke volume
(increased)
Cardiac output
(increased)
Arterial pressure
(increased)
Tumour perfusion
(increased)
Vascular shear stress
(increased)
Vascular maturation
O2 delivery
(increased)
Tumour perfusion
pressure
(increased)
O2 diffusion distance
(increased)
Hypoxia
(decreased)
Heart rate
(increased)Mild hyperthermia
Vasodilation
Systemic
effect
Chronic
adaptation
Acute
response
Tumour
microenvironment Reduced diffusion-limited hypoxia
Reduced perfusion-
limited hypoxia
Fig. 2 Potential mechanism of
exercise-modulated tumour
perfusion and hypoxia.
Systemic effects of augmented
cardiac output and increased
arterial pressure resulting from
mild hyperthermia and increased
stroke volume and heart rate in
response to acute exercise (top
panel) may influence local
physiological responses and
vascular adaptation in the
tumour microenvironment
(bottom panel). Improved
tumour perfusion, either as a
result of increased systemic
blood flow during exercise or as
a result of vascular maturation,
may enhance acute and chronic
oxygenation of hypoxic tumour
areas, thus resulting in improved
radiotherapy efficacy.
O. Schumacher et al.
vascular remodelling, namely angiogenesis and arteriogen-
esis [54, 55]. The same structural remodelling of the vas-
culature in response to exercise may also take place in
tumours, thus potentially improving oxygenation in the
same way it does in working muscles during and after
exercise. Moreover, under acute exercise conditions,
mechanical forces exerted on vessel walls increase with
increasing exercise intensity and are thought to promote the
development of functional mature vasculature [56, 57].
Translated to dysfunctional tumour vasculature, exercise
may result in the development of more mature and less
permeable blood vessels that function more normally. Fur-
thermore, increased heart rate and stroke volume during
exercise result in augmented cardiac output and increase
systemic blood flow, potentially also enhancing perfusion of
tumour tissue. Together with increased tumour blood flow
as a result of vasodilation mediated by mild hyperthermia
that may occur during exercise and increases in mean
arterial pressure that could result in an increased oxygen
diffusion distance within the tumour, there are several
potential exercise-related mechanisms that may alleviate
tumour hypoxia and therefore enhance treatment response
to radiotherapy (Fig. 2).
Exercise modulation of tumour perfusion
and hypoxia
As detailed above, physical activity has been associated
with a reduced risk of PCa progression and mortality
[40, 41]. However, little is known about the underlying
biological mechanisms that delay progression and improve
survival in PCa patients. Potential mechanisms have been
summarised by Galvão et al. [58] and include, among
others, changes in tumour vascularisation that may permit
better drug delivery and oxygenation of the tumour through
improved perfusion [58]. Indeed, tumour vessel morphol-
ogy has been associated with survival outcomes in men
diagnosed with PCa. Mucci et al. [59] evaluated whether
tumour microvessel morphology would predict PCa mor-
tality among 572 men in the prostatectomy cohort of the
Health Professionals Follow-up Study. While greater
microvessel density (MVD) was associated with extrapro-
static extension it was not a predictor of mortality in this
analysis. However, the authors found that men with tumours
containing the smallest (area and diameter) and most irre-
gularly shaped vessels had a ~6 times and ~17 times higher
likelihood of developing lethal PCa, respectively.
In a further investigation, also based on data from the
Health Professionals Follow-up Study, Van Blarigan et al.
[60] examined whether physical activity was associated
with tumour vessel morphology in men with PCa.
They found that men who reported a brisk walking paceTa
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of ≥4.8 km/h had larger, more regularly shaped blood ves-
sels compared to men who reported walking at <4.8 km/h.
However, there was no association between brisk walking
and MVD, and the duration of physical activity (vigorous
and non-vigorous) was not associated with tumour blood
vessel size, shape or number [60].
In the following sections, we discuss the clinical and
preclinical work that has been done to further shed light on
potential mechanisms and how they might affect treatment
outcomes. These sections are not intended to be an
exhaustive review of the relevant literature that examine
exercise as an adjunct therapy in cancer or a means to
improve treatment outcomes. Rather, they are intended
to provide an extensive overview of the efficacy of exercise
to modulate tumour vasculature, perfusion and hypoxia as
well as how these adaptations might translate to improved
treatment outcomes. A literature search was conducted in
Embase, MEDLINE and PubMed using the search terms
exercise AND (cancer OR tumour) AND (perfusion OR
blood flow OR hypoxia OR oxygen OR vascularity OR
vascular OR vessels) as well as exercise AND prostate
cancer AND (radiotherapy OR radiation), and last updated
in February 2020.
Preclinical studies
Aerobic exercise has been linked to a reduction in tumour
incidence, growth and metastasis across a variety of pre-
clinical tumour models. However, meaningful comparisons
and conclusions from current evidence is limited due to
considerable heterogeneity in the methods used across dif-
ferent studies [61]. It has been proposed that exercise can
directly impact tumour physiology and improve anti-cancer
treatment efficacy, thus highlighting the potential of exer-
cise to control disease progression [62]. One
important mechanism by which exercise may govern these
processes is modulation of tumour vascularisation and
perfusion [63].
Acute exercise responses
Compared with short- as well as long-term exercise training
interventions, few studies have investigated how an acute
bout of exercise may affect tumour physiology (Table 1).
Using a preclinical PCa model, McCullough et al. [64]
published the first study to investigate tumour blood flow
in vivo during exercise. The authors demonstrated that
compared to resting conditions, exercise comprised of
forced treadmill running significantly increased tumour
blood flow by ~200% as well as the number of perfused
blood vessels, with hypoxia decreased by ~50%. These
results were later replicated by Garcia et al. [65], who used a
similar exercise protocol in a PCa model and demonstrated
that exercise increased tumour blood flow by ~180%
compared to resting conditions. Interestingly, this response
was only observed in orthotopic tumours mimicking the
physiological conditions of primary cancers. Ectopic
tumours, which could be regarded as metastatic lesions,
showed a decrease in blood flow of ~25% in response to
exercise.
Miller et al. [66] and Schadler et al. [67] used radio-
nuclide uptake and intratumoral doxorubicin levels as sur-
rogate markers for tumour perfusion, respectively. Whereas
Miller et al. [66] found an increased concentration of
radiotracers with high-intensity exercise compared to a
hypotensive low-perfusion state induced by anaesthesia,
Schadler et al. [67] found no difference in doxorubicin
levels after low-intensity exercise compared to mice not
undergoing exercise. Despite exercising for more than twice
the amount of time (45 vs. 20 min), the mice in the
experiment by Schadler et al. [67] only exercised at half the
intensity (10 vs. 20 m/min), which likely resulted in overall
lower mean arterial pressure compared to the experiment by
Miller et al. [66] and therefore could have resulted in lower
tumour perfusion pressure and hence lower tumour blood
flow. Indeed, preliminary data from Lønbro et al. [68]
suggest that it is only high-intensity exercise and not low- or
moderate-intensity exercise that results in decreased intra-
tumoral hypoxia.
The studies by McCullough et al. [64] and Garcia et al.
[65] both also investigated in vitro vascular responsive-
ness to norepinephrine. In tumour arterioles, vasocon-
striction was blunted by approximately 95% compared
with control prostate vessels [64], and although there was
no difference in vasoreactivity between orthotropic and
ectopic tumours, vasoconstriction was severely reduced
compared with host prostate tissue from healthy control
animals [65]. This blunted vascular responsiveness is
potentially what allows tumour perfusion to be either
maintained or increased during exercise, when blood
would otherwise normally be diverted away from internal
organs to working muscles. Importantly, the resulting
increase in tumour blood flow may play a critical role in
improving oxygenation for radiotherapy as well as
tumour-targeting drug delivery. Additionally, it has been
proposed that acute systemic effects of exercise in com-
bination with increased tumour perfusion may contribute
to slower tumour progression [62]. However, it is cur-
rently unknown for how long after exercise these changes
in tumour perfusion last and hence when the optimal time
would be to exercise in relation to treatment, or at which
point there is no added benefit of exercise. Furthermore, it
is unclear what exercise prescription in terms of intensity
and duration would provide the most potent stimulus that
is both feasible and produces a clinically meaningful
response.
O. Schumacher et al.
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Adaptations to exercise training
Several animal model studies, predominantly in lymphoma,
breast and PCa, that investigated the effect of exercise
training on tumour physiology, including vascular function
and hypoxia, also assessed tumour growth. In studies by
Jones et al. [69, 70], tumour growth rate was comparable
between exercise groups who had voluntary access to a
running wheel and non-exercising control groups. On the
other hand, exercise significantly reduced tumour growth in
a murine breast cancer model [71]. Buss and Dachs [72]
also found that voluntary wheel running slowed tumour
growth rate in hyperlipidemic mice. However, this was only
the case for mice with high muscular cytochrome c oxidase
subunit IV (COX-IV) expression (a biomarker used for the
level of exercise), suggesting that only mice with higher
exercise volumes experienced a reduction in tumour growth
rate [72]. Moreover, exercise appeared to suppress the for-
mation and growth of metastases in exercising animals
[69, 72]. The anti-metastatic effect of exercise may be
linked to its ability to alter vascular permeability through
modulation of redox-sensitive small GTPase activity,
thereby preventing cancer cells from easily crossing the
vessel wall, making it more difficult to establish metastatic
sites [73]. Indeed, studies by Wolff et al. showed that
running distance was inversely correlated with activation of
the redox-sensitive small GTPase Rho [74], and that exer-
cise maintained blood–brain barrier integrity, thus pre-
venting tumour cells from extravasating into the brain [75].
An overview of the studies investigating the impact of
exercise training on tumour vasculature in an attempt to
alleviate hypoxia and improve treatment response are pre-
sented in Table 2. Both short-term and long-term exercise
training, in the form of voluntary wheel running or forced
treadmill running, appear to improve intratumoral vascu-
lature. However, while changes in vessel number and size
as well as MVD are inconsistent, findings of increased
vessel maturity and function that allow for tumours to be
perfused more uniformly and thus increase microvascular
PO2 are more conclusive. Schadler et al. [67] postulated that
increased shear stress exerted on endothelial cells during
aerobic exercise plays an important role in the remodelling
of tumour blood vessels, allowing for greater blood flow to
the tumour. In addition, McCullough et al. [76] found that
temporal variations in microvascular PO2 were reduced in
exercise-trained animals compared to sedentary control rats
in an orthotopic PCa model. Studies have also shown that
the number of patent and perfused vessels increased after
exercise training, resulting in a larger percentage and less
heterogeneously perfused tumour area [67, 69, 70, 77].
These changes in vascularisation and improvements in
perfusion were accompanied by a reduction in tumour
hypoxia [71, 72, 76, 78, 79], and mice with high COX-IV
expression had significantly lower levels of hypoxia com-
pared to mice with low levels of COX-IV expression [72].
Effect of exercise on radiotherapy treatment response
To date, only one study has investigated the effect of
exercise in combination with radiotherapy on treatment
outcomes [80]. Dufresne et al. injected human PCa PPC-1
cells subcutaneously into male athymic nude mice and
subjected them to exercise 5 days/week for 25–60 min/day
over 2 weeks in combination with a total of 20 Gray (Gy)
fractionated into four doses of 5 Gy each. Mice were ran-
domised to either no exercise (control), exercise only,
radiotherapy only, or exercise plus radiotherapy. In contrast
to previous studies, exercise alone did not increase tumour
vascularisation; however, radiotherapy (with or without
exercise) did. Radiotherapy further caused an increase in
natural killer cell infiltration and activity that resulted in
increased tumour cell apoptosis. Interestingly, this response
was potentiated when exercise was combined with radio-
therapy [80]. These results are exciting and provide pre-
liminary preclinical evidence on the application of exercise
as an adjunct therapy during radiotherapy in PCa.
Clinical studies
Despite the large number of clinical studies in the field of
exercise oncology and although preclinical studies have
produced promising results, very few clinical studies have
actually investigated the effect of either an acute bout of
exercise or prolonged exercise training on tumour vascu-
lature, perfusion and hypoxia in humans. To our knowl-
edge, only two studies have been conducted in a clinical
population [77, 81] (Table 2). Jones et al. [81] performed a
pilot study where they allocated 20 women with operable
breast cancer receiving neoadjuvant chemotherapy to either
chemotherapy alone or chemotherapy plus aerobic exercise
training, consisting of thrice weekly cycling on a stationary
ergometer at 60–100% of peak oxygen consumption for
30–45 min/session. At baseline and after 9 weeks of the
intervention (i.e. after three cycles of chemotherapy),
tumour blood flow was assessed using 15O-labelled water
positron emission tomography (PET). In the exercise group,
tumour blood flow decreased by an average of 38%.
However, the analysis was limited by the fact that pre/post
PET scans were only available for five women in the
exercise group (for two women in the control group for
whom pre/post PET scans were available data were not
reported). Further immunohistochemical analysis of tumour
biopsies at the same time point (i.e. after 9 weeks of the
intervention) revealed no difference between groups in
relation to markers of hypoxia and MVD. However, similar
to the PET assessment, tissue samples were only available
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for a small number of patients due to pathologic complete
response rates to chemotherapy treatment.
In contrast, Florez Bedoya et al. [77] assessed tumour
vessel morphology in tissue samples from 23 pancreatic
ductal adenocarcinoma patients participating in an exercise
intervention during preoperative chemo- or chemoradiation
therapy and compared them to 13 historical controls (i.e.
tumour samples from patients not undergoing exercise prior
to surgery). The authors reported that 2 h/week of pre-
scribed home-based exercise training resulted in remodel-
ling of the tumour vasculature. Specifically, the total
number of vessels, the number of elongated vessels, MVD
as well as the number of open vessel lumens were all
increased in samples from the exercise group compared
with control samples. In theory, these vascular adaptations
could result in improved chemotherapy and/or oxygen
delivery to the tumour and hence improve clinical out-
comes. However, further clinical studies are warranted to
confirm these results and evaluate the effects of exercise-
induced vascular remodelling on treatment efficacy as well
as long-term outcomes.
Neoadjuvant and pre-surgical settings provide an excel-
lent opportunity to study some of these outcomes. Indeed,
several clinical trials are currently ongoing or have recently
been completed and are pending publication of results,
which will add to this body of knowledge. The majority of
these registered studies are being conducted in PCa patients,
either investigating vascular adaptations in response to
exercise training prior to prostatectomy and subsequently
analysing resected tumour tissue samples for tumour vessel
morphology and hypoxic tumour area as well as intratu-
moral natural killer cell infiltration (ClinicalTrials.gov
Identifier: NCT02954783 and NCT03365076), or investi-
gating changes in tumour perfusion and hypoxia in response
to acute exercise exposure using either magnetic resonance
imaging or by pathological analysis of tumour tissue sam-
ples excised during radical prostatectomy (ANZCTR
Registration number: ACTRN12620000432910; Clin-
icalTrials.gov Identifier: NCT03675529). These studies will
add further information regarding exercise as a potential
modulator of the TME in clinical populations and provide
insight into mechanistic pathways.
Implications for future research
Whereas initial clinical research shows mixed results, pre-
clinical studies indicate that exercise may beneficially alter
tumour physiology. In addition, one study in a PCa mouse
model found that exercise increases the efficiency of
radiotherapy, resulting in decreased tumour growth. These
findings are promising and should encourage further
investigation into this novel area of exercise and PCa
research. However, given the paucity of research to date it is
unclear what exercise prescription would deliver the desired
outcome. Furthermore, specific tumour characteristics such
as the initial degree of vascularity and metabolism will
likely also influence outcome measures such as hypoxia and
should be taken into consideration when designing future
studies.
From a physiological perspective, the FITT principles of
training, i.e. frequency, intensity, time (duration) and type
of exercise should be considered as a starting point to for-
malise structured research questions. Different exercise
intensities and types (e.g. aerobic vs. resistance training) are
associated with distinct biochemical as well as physiologi-
cal adaptations that may differentially affect tumour phy-
siology. Furthermore, not all frequency schedules will likely
be feasible for a specific exercise intensity (e.g. daily
exercise at high intensity) and carefully considered period-
isation schedules will need to be employed to maintain
exercise tolerability during treatment [44, 82].
A concept that could be particularly interesting in this
setting and patient population is the ‘minimal dose
approach’ to exercise [83]. Considering the busy appoint-
ment schedule of patients, the minimal effective ‘dose’ of
exercise (in terms of frequency, intensity and duration/time,
or volume) would be extremely valuable to minimise patient
burden. Hence, establishing or disproving dose–response
relationships as well as threshold or ceiling effects will be
essential to facilitate research translation into clinical prac-
tice. Similar to pharmaceutical drugs, exercise will likely
also have a therapeutic window, where a certain minimal
‘dose’ is required to produce a desired effect and an upper
tolerable ‘dose’ that will determine what is actually feasible
for patients to safely accomplish.
In addition to the FITT principles of training, the timing
of exercise in relation to treatment is likely to also be of
importance. To achieve an oxygen enhancement effect for
radiotherapy, the timing of exercise (i.e. pre-radiation)
seems crucial, given that cellular oxygen is required at the
time of radiation. Also, a distinction should be made
between acute physiological changes and structural vascular
adaptations that may aid treatment delivery and improve
efficacy, including the time course in which these will
likely occur.
From a clinical point of view, safety and efficacy trials in
human populations are warranted. Although exercise is not
a drug, it does drive a myriad of endogenous molecules to
be produced that have influence locally and systemically as
well as the effects of physical loading on vessels and other
structures causing acute and chronic effects and adaptations.
Therefore, it has been proposed that combining exercise
with conventional cancer treatments should be held to the
same standards as other combination treatments when
evaluating treatment outcomes [84, 85]. Furthermore,
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logistical aspects that may affect the biological response
also need to be taken into account. For example, studies in
PCa patients investigating exercise in combination with
radiotherapy may consider the timing and quantity of fluid
intake before radiotherapy sessions, as gastrointestinal
passage time and thus urine production may be affected by
certain exercise durations and intensities. This may affect
the positioning of the tumour mass due to fluctuating
bladder volumes and ultimately lead to less radiation dose
being delivered to the tumour and cause more toxicity to
surrounding tissues.
Despite these potential challenges of implementing such
trials, they will be a valuable addition to our understanding
of the interaction between exercise and the TME and, if
shown to be effective, will have clinical implications
beyond the PCa population. However, men with PCa may
particularly benefit from these developments, as initial
observations appear to indicate that exercise of at least
moderate intensity is required to elicit beneficial effects (i.e.
increased tumour perfusion and subsequently reduced
hypoxia). Men with PCa are usually relatively asympto-
matic with respect to their disease and probably have a
higher exercise capacity than many other cancer groups,
such as pancreatic cancer patients, thus allowing them to
exercise at an intensity to gain a benefit. Furthermore, men
awaiting radical prostatectomy represent an ideal cohort to
study these interactions as it allows researchers to directly
study the impact of exercise on the tumour without the
interference of neoadjuvant treatments and without
having patients undergo additional invasive procedures to
acquire tissue samples required to investigate potential
mechanisms.
Collectively, further research in this area will add to
the understanding of the underlying biological mechan-
isms of combination treatments involving exercise and
address safety as well as dosing considerations important
to both patients and clinicians. As a first important step,
however, studies should address proof-of-concept out-
comes such as short- and/or long-term reductions in
tumour hypoxia as well as acute and chronic tumour
perfusion changes as a result of exercise. We suggest
these studies should incorporate non-invasive functional
imaging modalities and immunohistochemical techniques
to monitor tumour responses and pinpoint molecular
mechanisms, with closely defined and reported patient
populations and tumour characteristics as well as exercise
prescription parameters to then develop more targeted
interventions. Potentially, the findings of these studies
will change best practice in radiation oncology with
patients completing brief exercise bouts immediately (or
shortly) before radiation doses, which may result in
increased therapy success and a greater rate of cancer cure
or delayed disease progression.
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